Loading…
Grifols, S.A. is projected to rise to $9.76 by 2027, a +19% move from its current price of $8.20. GRFS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $8.06 | $8.20 | $8.35 | +0.05% |
| Aug 2 | $8.01 | $8.21 | $8.41 | +0.11% |
| Aug 3 | $7.97 | $8.21 | $8.47 | +0.16% |
| Aug 4 | $7.94 | $8.22 | $8.51 | +0.21% |
| Aug 5 | $7.91 | $8.22 | $8.55 | +0.27% |
| Aug 6 | $7.88 | $8.23 | $8.59 | +0.32% |
| Aug 7 | $7.86 | $8.23 | $8.62 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.86 | $8.23 | $8.62 | +0.37% |
| Week 2 | $7.74 | $8.26 | $8.82 | +0.75% |
| Week 3 | $7.65 | $8.29 | $8.98 | +1.13% |
| Week 4 | $7.59 | $8.32 | $9.13 | +1.51% |
| Week 5 | $7.53 | $8.35 | $9.26 | +1.89% |
| Week 6 | $7.49 | $8.39 | $9.39 | +2.27% |
| Week 7 | $7.45 | $8.42 | $9.51 | +2.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Grifols, S.A. is a healthcare company that engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.
Additionally, Grifols provides biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. The company also offers healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance, high-tech solutions to automate hospital processes, clinical nutrition, and medical devices encompassing instrumentation and disposable materials for various hospital services, as well as manufacturing services to third parties and research activities. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Grifols, S.A. (GRFS) is a healthcare company focused on plasma-derived medicines and related products. The stock is trading at $7.88 with a market capitalization of $5.36B and a market rank of 1267.
The long-range forecast path shows rising averages through 2050, with the 2026 avg at $7.88, 2030 avg at $11.82, 2040 avg at $29.48, and 2050 avg at $51.66. The forecasted extremes reach a max of $16.11 in 2030 and $84.45 in 2050, indicating substantial long-term upside. ROI figures rise from 50 by 2030 to 555.5 by 2050, with bullish sentiment strengthening in later years.
A major floor 19.2% below — a decisive break under it would weaken the trend.
The nearest floor, 14.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 9.6% above — clearing it would confirm fresh momentum.
Key GRFS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GRFS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.94 | Buy | $7.99 | Buy |
| MA 10 | $7.77 | Buy | $7.81 | Buy |
| MA 20 | $7.49 | Buy | $7.64 | Buy |
| MA 50 | $7.54 | Buy | $7.63 | Buy |
| MA 100 | $7.81 | Buy | $7.87 | Buy |
| MA 200 | $8.44 | Sell | $8.22 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.76 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 156.41 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 16.81 | Buy |
| Bollinger %B (20,2) | 1.01 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.10 | Buy |
| Awesome (5,34) | 0.49 | Buy |
| Ultimate (7,14,28) | 69.10 | Neutral |
| Momentum (10) | 0.87 | Buy |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 8.16 | Buy |
| ADX (14) | 19.67 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is mixed but tilted toward upside, with a bullish overall tone. The RSI(14) is 70, suggesting near-overbought conditions, while the 50-day simple moving average sits at $7.53 and the 200-day simple moving average at $8.50.
Near-term support is identified at $7.02 and resistance at $7.88. The stock has traded in a 30-day range from $7.09 to $8.76, reflecting a constructive-but-cautious momentum as price tests the near-term levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.02 | $8.20 | $10.62 | 0% | Neutral | |
| $8.01 | $9.76 | $12.44 | +19% | Neutral | |
| $8.57 | $10.65 | $13.95 | +30% | Bullish | |
| $9.21 | $11.63 | $15.56 | +42% | Bullish | |
| $10.39 | $13.29 | $18.10 | +62% | Bullish | |
| $11.58 | $14.99 | $20.74 | +83% | Bullish | |
| $13.82 | $18.11 | $25.41 | +121% | Bullish | |
| $15.50 | $20.51 | $29.16 | +150% | Bullish | |
| $15.23 | $20.36 | $29.29 | +148% | Bullish | |
| $16.41 | $22.14 | $32.21 | +170% | Bullish | |
| $24.99 | $35.17 | $53.63 | +329% | Bullish | |
| $41.90 | $63.25 | $103.39 | +671% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.02 | $8.20 | $9.55 | +0.00% |
| August 2026 | $7.18 | $8.37 | $9.95 | +2.11% |
| September 2026 | $7.34 | $8.61 | $10.33 | +2.82% |
| October 2026 | $7.27 | $8.56 | $10.34 | -0.57% |
| November 2026 | $7.18 | $8.49 | $10.32 | -0.80% |
| December 2026 | $7.32 | $8.68 | $10.62 | +2.27% |
Click any year to see its month-by-month GRFS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect GRFS to range from $7.02 to $10.62 through 2026. The $8.20 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The GRFS price prediction for 2027 points to an average of $9.76 (low $8.01, high $12.44) — a potential gain of +19% on today's $8.20. Price action looks broadly range-bound.
In 2028, GRFS is projected to trade between $8.57 and $13.95, averaging $10.65 — a potential gain of +30% from today's $8.20. That is up +9% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Grifols, S.A.'s 2029 outlook centres on $11.63, within a $9.21 to $15.56 range. That is up +9% on the projected 2028 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2030, GRFS could reach as high as $18.10, with a base case around $13.29 and support toward $10.39 — roughly +62% from $8.20. Buyers look set to stay in control over this stretch.
Expect GRFS to range from $11.58 to $20.74 through 2031. The $14.99 average target implies a +83% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The GRFS price prediction for 2032 points to an average of $18.11 (low $13.82, high $25.41) — a potential gain of +121% on today's $8.20. Buyers look set to stay in control over this stretch.
In 2033, GRFS is projected to trade between $15.50 and $29.16, averaging $20.51 — a potential gain of +150% from today's $8.20. That is up +13% on the projected 2032 average. Momentum favours further upside here.
Grifols, S.A.'s 2034 outlook centres on $20.36, within a $15.23 to $29.29 range. That is -1% versus the projected 2033 average. That marks a +148% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, GRFS could reach as high as $32.21, with a base case around $22.14 and support toward $16.41 — roughly +170% from $8.20. Momentum favours further upside here.
Expect GRFS to range from $24.99 to $53.63 through 2040. The $35.17 average target implies a +329% move from current prices. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The GRFS price prediction for 2050 points to an average of $63.25 (low $41.90, high $103.39) — a potential gain of +671% on today's $8.20. Momentum favours further upside here.
Investing $1,000 in GRFS today (≈ 121.95122 GRFS) could be worth
$7,713.7
+$6,713.7 (+671%) by 2050 · US Dollar
Based on the average projected GRFS price of $63.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GRFSwould be worth at today's price.
$1,000 invested in GRFS on Jul 30, 2025 (≈ 92.165895 GRFS) would be worth
$755.76
-$244.24 (-24.4%) today · 0.76× · US Dollar
Based on a GRFS entry price of $10.85 vs. today's $8.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.54 | $1,087.53 | +8.8% |
| 1 month ago | $7.08 | $1,158.19 | +15.8% |
| 3 months ago | $8.23 | $996.35 | -0.4% |
| 6 months ago | $9.25 | $886.49 | -11.4% |
| 1 year ago | $10.85 | $755.76 | -24.4% |
| All time (5.0y) ago | $15.25 | $537.7 | -46.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GRFS forecast.
Our base-case forecast reaches $16.00 around 2032.
Implied market cap at $16.00: $4.13B
The multi-year forecast points to meaningful upside, with the average price rising from $11.82 in 2030 to $29.48 by 2040 and $51.66 by 2050. The implied maximums also widen, to $16.11 in 2030, $44.95 in 2040, and $84.45 in 2050. These trajectories correspond to ROI figures of 50 (2030), 274.1 (2040), and 555.5 (2050), with a bullish sentiment noted for the later years.
These estimates imply substantial long-term appreciation, but they are not guaranteed and remain subject to market and sector risks.
Overall, the forecast suggests a path of expanding value into the late 2040s and beyond, underscoring the potential for notable gains if the underlying drivers materialize while acknowledging the inherent uncertainty in long-horizon projections.
Tap a question to reveal the answer.
2030 forecast: min $9.24, avg $11.82, max $16.11; ROI 50; sentiment BULLISH.
The forecast shows bullish sentiment from 2028 onward, with 2030 avg $11.82 and 2050 avg $51.66 and ROI up to 555.5, but these are estimates and not guaranteed.
Yes, the 2050 forecast max is $84.45, with an avg of $51.66 and ROI 555.5; sentiment BULLISH.
Current price is $7.88. The 30-day range is from $7.09 to $8.76.
2040 forecast: min $20.94, avg $29.48, max $44.95; ROI 274.1; sentiment BULLISH.
Grifols, S.A. Community Discussion
0Share your Grifols, S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.